The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Treatments Under Investigation for Metastatic TNBC

Targeted Oncology
Published Online:12:37 PM, Mon April 15, 2019

Sarah S. Mougalian, MD: In terms of developments in the treatment of metastatic triple-negative breast cancer, we now have the combination of atezolizumab and nab-paclitaxel for patients whose tumor-infiltrating immune cells express PD-L1.

We are looking for results from major clinical trials regarding the use of novel antibody drug conjugates. For example, sacituzumab govitecan targeting Trop-2, as well as ladiratuzumab vedotin targeting LIV1A.

There are ongoing clinical trials with regards to the use of platinum-containing regimens in the adjuvant setting, as well as adjuvant regimens containing PARP inhibitors for women with BRCA mutations.

Immunotherapy may be an appropriate and attractive option for some select women with metastatic triple-negative breast cancer. It’s important to remember that PD-L1 testing should be done on the tumor-infiltrating immune cells in this setting. Clinical trials should be considered for all women with metastatic triple-negative breast cancer, as this remains an aggressive and difficult-to-treat population. Neoadjuvant chemotherapy for triple-negative breast cancer should also be considered for all but the smallest of triple-negative cancers in the fit patient.

Further in the future, we’ll be looking for the results of clinical trials targeting specific mutations in this setting.

Transcript edited for clarity.

Sarah S. Mougalian, MD: In terms of developments in the treatment of metastatic triple-negative breast cancer, we now have the combination of atezolizumab and nab-paclitaxel for patients whose tumor-infiltrating immune cells express PD-L1.

We are looking for results from major clinical trials regarding the use of novel antibody drug conjugates. For example, sacituzumab govitecan targeting Trop-2, as well as ladiratuzumab vedotin targeting LIV1A.

There are ongoing clinical trials with regards to the use of platinum-containing regimens in the adjuvant setting, as well as adjuvant regimens containing PARP inhibitors for women with BRCA mutations.

Immunotherapy may be an appropriate and attractive option for some select women with metastatic triple-negative breast cancer. It’s important to remember that PD-L1 testing should be done on the tumor-infiltrating immune cells in this setting. Clinical trials should be considered for all women with metastatic triple-negative breast cancer, as this remains an aggressive and difficult-to-treat population. Neoadjuvant chemotherapy for triple-negative breast cancer should also be considered for all but the smallest of triple-negative cancers in the fit patient.

Further in the future, we’ll be looking for the results of clinical trials targeting specific mutations in this setting.

Transcript edited for clarity.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.